Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IMMUTEP LIMITED Director's Dealing 2025

Oct 7, 2025

65122_rns_2025-10-07_96777b70-6ea9-466a-966e-4953d3088f54.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity IMMUTEP LIMITED (ASX:IMM) ABN 90 009 237 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Dr Frederic Triebel
Date of last notice 8 April 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.
Date of change 1 October 2025
No. of securities held prior to change 10,453,764Fullypaidordinaryshares (ASX: IMM)3,600,000PerformanceRights(ASX: IMMAM)17,061AmericanDepositoryReceipts (ADRs). Note that the ADRtoFPORatiois1:10
Class 1.) Fully Paid Ordinary Shares2.) Performance Rights
Number acquired 900,000 Fully Paid Ordinary Shares (ASX:IMM)
Number disposed 900,000PerformanceRights(ASX:IMMAM)
  • See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation Nil for the issue of 900,000 shares. Noamount is payable upon exercise of the 3rdtranche of Performance Rights which wereapproved by shareholders at the 2021 AGM.
No. of securities held after change 11,353,764Fullypaidordinaryshares (ASX” IMM)2,700,000PerformanceRights(ASX: IMMAM)17,061American Depository Receipts(ADRs). Note that the ADR to FPORatio is 1:10
Nature of changeExample: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participation inbuy-back 900,000 shares were issued upon vesting andexercising of the 3rdtranche of PerformanceRights out of the 2,700,000 PerformanceRights which were issued to Dr Triebel inaccordancewithshareholderapprovalobtained at the 2021 AGM. One ordinaryfully paid share was acquired for eachPerformanceRight that vested.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest
Name of registered holder(if issued securities)
Date of change
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed
Interest acquired
Interest disposed
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation
Interest after change
  • See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required? N/A
If so, was prior written clearance provided to allow the tradeto proceed during this period? No
If prior written clearance was provided, on what date was thisprovided? No
  • See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3